10.01.2012
Belarus to set up new company for processing plasma
MINSK, 10 January (BelTA) – The National Research Center for Blood Transfusion and Medical Biotechnology is to open a new facility to process donor plasma that will be the only one of the kind in the CIS, BelTA learnt from Deputy Director of the center Sergei Leshchuk.
The investment project was initiated by the Health Ministry. In 2012 the Health Ministry is going to hold a tender to choose an investor and complete design works. The interest in the construction of the unique facility has been shown by Russian, Chinese and German companies. According to preliminary estimates, the project will pay off in five years; an investor will be able to get invested money back within 7-8 years after the company starts operating at its full capacity.
The new company will process 50,000 liters of donor plasma per year. The capacities might be increased to 75,000 liters. The aim of the project is to produce preparations needed during surgeries, to treat hemophilia and other diseases. The implementation of the investment project will meet the domestic needs for major preparations obtained from blood plasma, Sergei Leshchuk said. The National Research Center for Blood Transfusion and Medical Biotechnology will be able to increase six times the production of these products.
This project is aimed to ease Belarus reliance on imports of drugs made from plasma. The country will be able to save up to €6.5 million per year. Some of domestically produced plasma products might be sold abroad.
The National Research Center for Hematology and Blood Transfusion was set up in 2004 after the merger of the Research Center for Hematology and Blood Transfusion and the National Blood Transfusion Center. In January 2012 it was renamed into the National Research Center for Blood Transfusion and Medical Biotechnology. The center studies blood diseases, develops blood diagnostic methods, improves blood transfusion procedures, develops genetically engineered blood proteins. The center provides scientific and methodological support for 20 blood transfusion stations and 41 blood transfusion divisions.
The investment project was initiated by the Health Ministry. In 2012 the Health Ministry is going to hold a tender to choose an investor and complete design works. The interest in the construction of the unique facility has been shown by Russian, Chinese and German companies. According to preliminary estimates, the project will pay off in five years; an investor will be able to get invested money back within 7-8 years after the company starts operating at its full capacity.
The new company will process 50,000 liters of donor plasma per year. The capacities might be increased to 75,000 liters. The aim of the project is to produce preparations needed during surgeries, to treat hemophilia and other diseases. The implementation of the investment project will meet the domestic needs for major preparations obtained from blood plasma, Sergei Leshchuk said. The National Research Center for Blood Transfusion and Medical Biotechnology will be able to increase six times the production of these products.
This project is aimed to ease Belarus reliance on imports of drugs made from plasma. The country will be able to save up to €6.5 million per year. Some of domestically produced plasma products might be sold abroad.
The National Research Center for Hematology and Blood Transfusion was set up in 2004 after the merger of the Research Center for Hematology and Blood Transfusion and the National Blood Transfusion Center. In January 2012 it was renamed into the National Research Center for Blood Transfusion and Medical Biotechnology. The center studies blood diseases, develops blood diagnostic methods, improves blood transfusion procedures, develops genetically engineered blood proteins. The center provides scientific and methodological support for 20 blood transfusion stations and 41 blood transfusion divisions.